Article thumbnail
Location of Repository

Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis

By Thomas O. Kovacs, James W. Freston, Marian M. Haber, Barbara Hunt, Stuart Atkinson and David A. Peura

Abstract

In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for ≤6 years to assess long-term maintenance therapy. Doses were adjusted depending on symptom response. Endoscopy was performed yearly. One hundred ninety-five subjects received lansoprazole for <1 to 72 months; most received daily doses of ≤30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for ≤72 months, with 39 subjects experiencing 50 recurrences. Most subjects (94–95%) had no or mild symptoms of day or night heartburn at study end, and 77% were asymptomatic at first erosive esophagitis recurrence. The most common treatment-related adverse events included diarrhea (10%), headache (8%), and abdominal pain (6%), and were mild or moderate in severity. Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for ≤6 years

Topics: Original Article
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:2702676
Provided by: PubMed Central

Suggested articles

Citations

  1. (2005). Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No.
  2. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
  3. (2001). Dutch study group: long-term lansoprazole treatment for gastro-esophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther.
  4. (2009). Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.
  5. (1995). Efficacy and safety of lansoprazole 15 mg OAD or 30 mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial. Gastroenterology.
  6. (1992). Epidemiology and natural history of gastrooesophageal reflux disease. Digestion.
  7. (2003). Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: metropole study results. Aliment Pharmacol Ther.
  8. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. Aliment Pharmacol Ther.
  9. Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
  10. (1996). Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci.
  11. (1999). Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
  12. Italian lansoprazole study group: daily low-dose versus alternate day fulldose lansoprazole in the maintenance treatment of reflux esophagitis.
  13. (1997). Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux esophagitis. Aliment Pharmacol Ther.
  14. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial).
  15. Lansoprazole for maintenance of remission of erosive esophagitis.
  16. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The lansoprazole maintenance study group.
  17. (1996). Lansoprazole versus omeprazole in long term maintenance treatment of refluxoesophagitis: a Scandinavian multicentre
  18. (2005). Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev.
  19. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci.
  20. (2001). Review article: long-term use of proton pump inhibitors in GERD––help or hindrance? Aliment Pharmacol Ther.
  21. (2004). Review article: the patient with gastro-esophageal reflux disease––lifestyle advice and medication. Aliment Pharmacol Ther.
  22. (2004). Review article: treatment for gastro-esophageal reflux disease––lifestyle advice and medication. Aliment Pharmacol Ther.
  23. Severe GERD: effective treatment prevents potentially serious complications.
  24. The continuum of GERD complications.
  25. (2005). Understanding GERD symptoms in the clinical setting. Drugs Today (Barc).

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.